Black Diamond Therapeutics Inc BDTX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-01-30 |
| Shares Out. | 57,300,000 |
| Website | blackdiamondtherapeutics.com/ ↗ |
| Phone | 16174175868 |
| Employees | 21 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$9.9M |
| Free Cash Flow | -$32.8M |
| Total Assets | $125.0M |
| Total Liabilities | $28.9M |
| Equity | $96.1M |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Black Diamond Therapeutics Inc is a publicly traded company under the ticker symbol BDTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-09-01)